This dataset provides ongoing reporting of confirmed (PCR) DC-resident COVID-19 positive cases. These data are dependent on accurate and timely reporting of COVID-19 positive cases by lab facilities. Data are presented by week of test collection; data show Sunday through Saturday of the same week. These data are subject to change on a weekly basis depending on lab facility reporting timelines and other factors. Data Sources: DC Health Notifiable Disease Surveillance System.

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. More information available at https://coronavirus.dc.gov.Data for overall Coronavirus cases and testing results. Demographics are presented by race, gender, ethnicity and age. Additional variables for personnel in the public safety, medical and human service workforce. District agencies are Metropolitan Police Department (MPD), Fire and Emergency Medical Services (FEMS), Department of Corrections (DOC), Department of Youth Rehabilitation Services (DYRS) and Department of Human Services (DHS). Data for Saint Elizabeth's Hospital available. DYRS, DOC and DHS further report on its resident populations. Visit https://coronavirus.dc.gov/page/coronavirus-data for interpretation analysis.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

District of Columbia COVID-19 positive cases and total tests reported by Ward. Due to rapidly changing nature of COVID-19, data for March 2020 is limited. General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

District of Columbia COVID-19 positive cases reported by DC Health Planning Neighborhoods. Due to rapidly changing nature of COVID-19, data for March 2020 is limited. General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. District of Columbia Department of Human Services testing for the number of positive tests, quarantined, returned to work and lives lost. Due to rapidly changing nature of COVID-19, data for March 2020 is limited.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. More information available at https://coronavirus.dc.gov. District of Columbia Department of Correction, both personnel and resident, testing for the number of positive tests, quarantined, returned to work, recovery and lives lost. Due to rapidly changing nature of COVID-19, data for March 2020 is limited.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. More information available at https://coronavirus.dc.gov. District of Columbia Child and Family Services Agency testing for the number of positive tests, quarantined, returned to work and lives lost. Due to rapidly changing nature of COVID-19, data for March 2020 is limited.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. District of Columbia Metropolitan Police Department testing for the number of positive tests, quarantined, returned to work and lives lost. Due to rapidly changing nature of COVID-19, data for March 2020 is limited.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. District of Columbia Fire and Emergency Medical Services testing for the number of positive tests, quarantined, returned to work and lives lost. Due to rapidly changing nature of COVID-19, data for March 2020 is limited.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. District of Columbia Department of Motor Vehicles testing for the number of positive tests, quarantined, returned to work and deaths. Due to rapidly changing nature of COVID-19, data for March 2020 is limited.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. District of Columbia Office of Unified Communications testing for the number of positive tests, quarantined, returned to work and lives lost. Due to rapidly changing nature of COVID-19, data for March 2020 is limited.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

States with high COVID-19 rates.

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. District of Columbia Saint Elizabeth's Hospital testing for the number of positive tests, quarantined, returned to work and lives lost. Due to rapidly changing nature of COVID-19, data for March 2020 is limited.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

On March 2, 2022 DC Health announced the District’s new COVID-19 Community Level key metrics and reporting. COVID-19 cases are now reported on a weekly basis. More information available at https://coronavirus.dc.gov. District of Columbia Department of Disability Services testing for the number of positive tests, quarantined, returned to work and lives lost. Due to rapidly changing nature of COVID-19, data for March 2020 is limited.General Guidelines for Interpreting Disease Surveillance DataDuring a disease outbreak, the health department will collect, process, and analyze large amounts of information to understand and respond to the health impacts of the disease and its transmission in the community. The sources of disease surveillance information include contact tracing, medical record review, and laboratory information, and are considered protected health information. When interpreting the results of these analyses, it is important to keep in mind that the disease surveillance system may not capture the full picture of the outbreak, and that previously reported data may change over time as it undergoes data quality review or as additional information is added. These analyses, especially within populations with small samples, may be subject to large amounts of variation from day to day. Despite these limitations, data from disease surveillance is a valuable source of information to understand how to stop the spread of COVID19.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 12 elements for all COVID-19 cases shared with CDC and includes demographics, any exposure history, disease severity indicators and outcomes, presence of any underlying medical conditions and risk behaviors, and no geographic data.

CDC has three COVID-19 case surveillance datasets:

• COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)
• COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)
• COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data cells are suppressed to protect individual privacy.
• The datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensures that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification (Interim-20-ID-02). The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC. COVID-19 case surveillance data are collected by jurisdictions and reported voluntarily to CDC.

For more information: NNDSS Supports the COVID-19 Response | CDC.

The deidentified data in the “COVID-19 Case Surveillance Public Use Data” include demographic characteristics, any exposure history, disease severity indicators and outcomes, clinical data, laboratory diagnostic test results, and presence of any underlying medical conditions and risk behaviors. All data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.

COVID-19 Case Reports

COVID-19 case reports have been routinely submitted using nationally standardized case reporting forms. On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19 included. Current versions of these case definitions are available here: https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/.

All cases reported on or after were requested to be shared by public health departments to CDC using the standardized case definitions for laboratory-confirmed or probable cases. On May 5, 2020, the standardized case reporting form was revised. Case reporting using this new form is ongoing among U.S. states and territories.

Data are Considered Provisional

• The COVID-19 case surveillance data are dynamic; case reports can be modified at any time by the jurisdictions sharing COVID-19 data with CDC. CDC may update prior cases shared with CDC based on any updated information from jurisdictions. For instance, as new information is gathered about previously reported cases, health departments provide updated data to CDC. As more information and data become available, analyses might find changes in surveillance data and trends during a previously reported time window. Data may also be shared late with CDC due to the volume of COVID-19 cases.
• Annual finalized data: To create the final NNDSS data used in the annual tables, CDC works carefully with the reporting jurisdictions to reconcile the data received during the year until each state or territorial epidemiologist confirms that the data from their area are correct.
• Access Addressing Gaps in Public Health Reporting of Race and Ethnicity for COVID-19, a report from the Council of State and Territorial Epidemiologists, to better understand the challenges in completing race and ethnicity data for COVID-19 and recommendations for improvement.

Data Limitations

To learn more about the limitations in using case surveillance data, visit FAQ: COVID-19 Data and Surveillance.

Data Quality Assurance Procedures

CDC’s Case Surveillance Section routinely performs data quality assurance procedures (i.e., ongoing corrections and logic checks to address data errors). To date, the following data cleaning steps have been implemented:

• Questions that have been left unanswered (blank) on the case report form are reclassified to a Missing value, if applicable to the question. For example, in the question “Was the individual hospitalized?” where the possible answer choices include “Yes,” “No,” or “Unknown,” the blank value is recoded to Missing because the case report form did not include a response to the question.
• Logic checks are performed for date data. If an illogical date has been provided, CDC reviews the data with the reporting jurisdiction. For example, if a symptom onset date in the future is reported to CDC, this value is set to null until the reporting jurisdiction updates the date appropriately.
• Additional data quality processing to recode free text data is ongoing. Data on symptoms, race and ethnicity, and healthcare worker status have been prioritized.

Data Suppression

To prevent release of data that could be used to identify people, data cells are suppressed for low frequency (<5) records and indirect identifiers (e.g., date of first positive specimen). Suppression includes rare combinations of demographic characteristics (sex, age group, race/ethnicity). Suppressed values are re-coded to the NA answer option; records with data suppression are never removed.

For questions, please contact Ask SRRG (eocevent394@cdc.gov).

Additional COVID-19 Data

COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths by state and by county. These

United States COVID-19: No. of States incl Washington DC w/ Confirmed Cases data was reported at 51.000 Unit in 16 May 2023. This stayed constant from the previous number of 51.000 Unit for 15 May 2023. United States COVID-19: No. of States incl Washington DC w/ Confirmed Cases data is updated daily, averaging 51.000 Unit from Jan 2020 (Median) to 16 May 2023, with 1228 observations. The data reached an all-time high of 51.000 Unit in 16 May 2023 and a record low of 1.000 Unit in 21 Jan 2020. United States COVID-19: No. of States incl Washington DC w/ Confirmed Cases data remains active status in CEIC and is reported by CEIC Data. The data is categorized under High Frequency Database’s Disease Outbreaks – Table US.D001: Center for Disease Control and Prevention: Coronavirus Disease 2019 (COVID-2019).

The data includes COVID-19 data on testing (overall number of tests, DC residents tested, total positive tests, number of deaths, and cleared from isolation), hospitals (ICU beds in hospitals, ventilators in hospitals, COVID-19 patients in DC hospitals including ICU, and percentage of pre-COVID Hospital Bed Capacity), fire and emergency services personnel, metropolitan police department personnel, department of corrections personnel and residents, department of youth rehabilitation services personnel and residents, office of unified communications personnel, department of human services personnel, department of motor vehicles personnel, dept of human services personnel, dept of child and family services personnel and residents (by positive cases, recovered and returned to work, quarantine, number of lives lost), and deaths by race, age, sex and wards. The data are compiled by the D.C. government in an xlsx file format. The data is open access and is available to the public. Data can be viewed on the website and can be downloaded (in the Previous Years' Data section).

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138